AUTHOR=Nan Feifei , Fu Xiaorui , Chen Xinfeng , Li Ling , Li Xin , Wu Jingjing , Feng Xiaoyan , Wu Xiaolong , Yan Jiaqin , Zhang Mingzhi 

TITLE=Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.929221

DOI=10.3389/fimmu.2022.929221

ISSN=1664-3224

ABSTRACT=<p>The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some patients are resistant to this treatment, leaving them with limited options. Therefore, strategies to overcome resistance to CAR-T cell therapy are needed. We retrospectively studied three R/R diffuse large B-cell lymphoma patients who were resistant to CAR-T cell therapy and whose disease was controlled after receiving pembrolizumab, 21D4 CAR-T cells, or ibrutinib and venetoclax. Some promising prevention and treatment strategies to overcome treatment resistance are also discussed.</p>